share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度報表
美股sec公告 ·  05/14 16:10
Moomoo AI 已提取核心訊息
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmicals Inc.（Conduit）公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲360萬美元，而去年同期的淨虧損爲170萬美元。研發費用爲12.8萬美元，這歸因於開發針對自身免疫性疾病的化合物 AZD1656 的共晶體。一般和管理費用增加了87％，達到280萬美元，這主要是由於工資和股票補償費用以及保險相關成本的增加。其他收入和支出導致淨支出爲597,000美元，主要是由於發行認股權證。據報道，利息支出爲11.9萬美元。Conduit的經營活動現金流淨使用額爲240萬美元。該公司沒有從事投資活動，本季度也沒有來自融資活動的現金流。Conduit的管理層正在尋求額外的資金來爲運營提供資金，並將繼續作爲持續經營企業。該公司的未來計劃包括通過開發來增加臨床資產，以及尋求合作伙伴關係以獲得許可機會。
Conduit Pharmicals Inc.（Conduit）公佈了截至2024年3月31日的季度財務業績。該公司的淨虧損爲360萬美元，而去年同期的淨虧損爲170萬美元。研發費用爲12.8萬美元，這歸因於開發針對自身免疫性疾病的化合物 AZD1656 的共晶體。一般和管理費用增加了87％，達到280萬美元，這主要是由於工資和股票補償費用以及保險相關成本的增加。其他收入和支出導致淨支出爲597,000美元，主要是由於發行認股權證。據報道，利息支出爲11.9萬美元。Conduit的經營活動現金流淨使用額爲240萬美元。該公司沒有從事投資活動，本季度也沒有來自融資活動的現金流。Conduit的管理層正在尋求額外的資金來爲運營提供資金，並將繼續作爲持續經營企業。該公司的未來計劃包括通過開發來增加臨床資產，以及尋求合作伙伴關係以獲得許可機會。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息